Loss per share
Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of share s of common stock outstanding during the period.
 
For periods of net income, and when the effects are
not
anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible notes using the if-converted method.
 
For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potential
dilutive common shares is anti-dilutive. The number of anti-dilutive shares, consisting of (i) common stock options, (ii) stock purchase warrants, and (iii) prior to the Merger closing in
April 2017
, convertible notes exercisable for or exchangeable into common stock, which have been excluded from the computation of diluted loss per share, was
3,575,928
shares and 
691,374
shares as of
June 30, 2017
and
2016,
respectively.

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Dipexium Pharmaceuticals, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

General statement of acquisition of beneficial ownership - Nov. 20, 2017
Dipexium Pharmaceuticals, Inc. Just Filed Its Quarterly Report: Loss per share Basic... - Nov. 9, 2017
Departure of Directors or Certain - Oct. 27, 2017

Auto Refresh

Feedback